Abecma is the first CAR T approved for use in earlier lines of therapy for patients with relapsed or refractory multiple myeloma in Japan – BMS
Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.